RecruitingNCT05020106

The Diagnostic Cut-off Value of Core Biomarkers of Alzheimer's Disease

Study on the Diagnostic Cut-off Value of Core Biomarkers in Cerebrospinal Fluid and Blood of Alzheimer's Disease

Sponsor

Capital Medical University

Enrollment

3,200 participants

Start Date

Sep 1, 2018

Study Type

OBSERVATIONAL

Conditions

Alzheimer s Disease

Summary

The participant in this study includes Alzheimer's disease (AD including familial AD and sporadic AD) patients, amnestic mild cognitive impairment (aMCI) patients, non-AD dementia patients and cognitively normal control. The purpose of this study is to establish the best cut-off value of cerebrospinal fluid (CSF) and blood β-amyloid (Aβ) 42/40, total tau (t-tau) , phosphorylated tau ,inflammatory factors, etc. in diagnosis of Alzheimer's disease (AD).

Eligibility

Min Age: 55 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study aims to establish standard diagnostic reference values (cut-off levels) for the core biomarkers used to diagnose Alzheimer's disease — such as amyloid and tau proteins — in a Chinese population. These biomarkers help doctors tell Alzheimer's apart from other types of dementia. **You may be eligible if...** - You are between 55 and 75 years old - You have been diagnosed with Alzheimer's disease, mild cognitive impairment (MCI), or a related dementia using established medical criteria - You are willing to provide informed consent (or your legal guardian can consent for you) **You may NOT be eligible if...** - You are outside the age range of 55–75 - You have a type of dementia not covered by this study - You have other major neurological or psychiatric conditions unrelated to Alzheimer's - You are unable or unwilling to complete study procedures Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.